XML 114 R98.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
 7 Months Ended 12 Months Ended
Dec. 28, 2022
Oct. 13, 2022
Jan. 07, 2022
Dec. 06, 2021
Sep. 02, 2021
Feb. 02, 2021
Jan. 14, 2021
Jan. 07, 2021
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Feb. 01, 2021
Subsidiary, Sale of Stock [Line Items]                        
Purchase of warrant             2,127,500         2,127,500
Sale of stock price per share   $ 10.00                    
Shares issued price per share                   $ 22.00    
Percentage for placement agent received discount and commissions           6.00% 6.00%          
Proceeds from issuance initial public offering                   $ 13,346,600  
Shares, cancelled                   3,250    
Number of shares issued, value   $ 15,000,000     $ 9,403,600         6,729,000  
Conversion price per share                   $ 20.00    
Preferred stock, redemption terms   The holders of the Series A Preferred Stock and Series B Preferred Stock have the right to require the Company to redeem their shares of the relevant series at a price per share equal to 105% of the stated value of such shares commencing (i) after the earlier of (1) the receipt of stockholder approval of the Amendments and (2) sixty (60) days after the closing of the 2022 Offering and (ii) before the date that is ninety (90) days after such closing. The Company has the option to redeem the Series A Preferred Stock and Series B Preferred Stock at a price per share equal to 105% of the stated value of such shares commencing after the 90th day following the closing of the 2022 Offering, subject to the holders’ rights to convert the shares prior to such redemption                    
Stock redeemed or called during period, value                   $ 15,750,000    
Carrying amount of redeemed                   13,365,000    
Loss on redemption                   2,385,000    
Number of shares issued 25,000                      
Net income attributable to noncontrolling interests                   $ 407,933 $ 56,453  
Nobility Healthcare LLC [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Noncontrolling shareholders ownership percentage                   49.00%    
Nobility Healthcare LLC [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Equity method investment, ownership percentage                   51.00%    
Stock Repurchase Program [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Number of repurchased shares                 273,041 186,299,000,000    
Number of repurchase                 $ 6,001,602      
Series A Convertible Redeemable Preferred Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Number of shares issued, shares   1,400,000                    
Preferred stock, par or stated value per share   $ 0.001                    
Series B Convertible Redeemable Preferred Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Number of shares issued, shares   100,000                    
Shares issued price per share   $ 9.50                    
Preferred stock, par or stated value per share   $ 0.001                    
Series B Preferred Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Preferred stock, voting rights                   The Certificate of Designation for the Series B Preferred Stock provides, in particular, that the Series B Preferred Stock will have no voting rights other than the right to vote on the Amendments and each share of Series B Preferred Stock entitles the holder thereof the right to cast 2,500 votes on the Amendments    
Stock redeemed or called during period, shares                   100,000    
Series A Preferred Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Stock redeemed or called during period, shares                   1,400,000    
Officers [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Common stock issuance granted     26,250                  
Vesting drescription               Such shares will vest over various periods ranging from one to five years on the anniversary of the grant date, provided that each grantee remains an officer or employee on such dates        
Employees [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Common stock issuance granted     9,500                  
Financial Advisor [Member] | Series A Convertible Redeemable Preferred Stock [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Reimbursement description   In connection with the 2022 Offering, the Company paid A.G.P./Alliance Global Partners (the “Financial Advisor”) an aggregate cash fee equal to $750,000 and reimbursed the Financial Advisor for certain of its expenses in an amount not to exceed $135,000                    
Aggregate cash fee   $ 750,000                    
Maximum [Member] | Stock Repurchase Program [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Proceeds from common stock       $ 10,000,000.0                
Maximum [Member] | Employees [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Vesting period     5 years                  
Minimum [Member] | Stock Repurchase Program [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Number of repurchase                   $ 4,026,523    
Minimum [Member] | Employees [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Vesting period     2 years                  
Warrant [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Sale of stock price per share           $ 65.00            
Underwritten Public Offering [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Equity method investment ownership percentage description             On January 14, 2021, the Company consummated a registered direct offering (the “Offering”) of (i) 140,000 shares of common stock (“Shares”), (ii) pre-funded warrants to purchase up to 360,000 shares of Common Stock (the “Pre-Funded Warrants”), issuable to investors whose purchase of shares of Common Stock would otherwise result in such investor, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the holder, 9.99%) of the Company’s outstanding Common Stock immediately following the consummation of the Registered Offering (“Pre-Funded Warrants”); and (iii) common stock purchase warrants (“Warrants”) to purchase up to an aggregate of 500,000 shares of Common Stock (the “Warrant Shares”), which are exercisable for a period of five years after issuance at an initial exercise price $65.00 per share, subject to certain adjustments, as provided in the Warrants.          
Number of shares issued, shares             140,000          
Purchase of warrant             500,000          
Warrants and rights outstanding, term             5 years          
Exercise price             $ 65.00          
Sale of stock price per share             $ 61.90          
Underwritten Public Offering [Member] | Pre Funded Warrants [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Purchase of warrant             360,000          
IPO [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Equity method investment ownership percentage description           the Company consummated an registered direct offering (the “Second Offering”) of (i) 162,500 shares of common stock (“February 2021 Shares”), (ii) pre-funded warrants to purchase up to 552,500 shares of Common Stock (the “February 2021 Pre-Funded Warrants”), issuable to investors whose purchase of shares of Common Stock would otherwise result in such investor, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the holder, 9.99%) of the Company’s outstanding Common Stock immediately following the consummation of the Registered Offering; and (iii) common stock purchase warrants (“February 2021 Warrants”) to purchase up to an aggregate of 715,000 shares of Common Stock (the “February 2021 Warrant Shares”), which are exercisable for a period of five years after issuance at an initial exercise price $65.00 per share, subject to certain adjustments, as provided in the February 2021 Warrants.            
Number of shares issued, shares           162,500 140,000          
Purchase of warrant           715,000            
Warrants and rights outstanding, term           5 years            
Exercise price           $ 65.00            
Sale of stock price per share           56.00 $ 61.90          
Shares issued price per share           $ 56.00 $ 61.90          
Proceeds from issuance initial public offering             $ 28,941,000          
IPO [Member] | Maximum [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Purchase of warrant             500,000          
IPO [Member] | Pre Funded Warrants [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Purchase of warrant           552,500 360,000          
Sale of stock price per share           $ 55.80 $ 61.70          
Shares issued price per share           $ 55.80 $ 61.70          
Proceeds from issuance initial public offering           $ 37,447,100 $ 29,013,000          
Share Price           $ 56.00            
IPO [Member] | Pre Funded Warrants [Member] | Maximum [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Purchase of warrant           715,000            
Proceeds from issuance initial public offering           $ 37,557,600            
IPO [Member] | February 2021 Shares [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Number of shares issued, shares           162,500            
IPO [Member] | February 2021 Pre-Funded Warrants [Member]                        
Subsidiary, Sale of Stock [Line Items]                        
Purchase of warrant           552,500            
Shares issued price per share           $ 55.80